Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure

Patients with relapsed/refractory multiple myeloma (RRMM) for whom the benefits of lenalidomide have been exhausted in early treatment lines need effective therapies. In cohort A of the phase 2 MM‐014 trial, we examined the safety and efficacy of pomalidomide plus low‐dose dexamethasone immediately...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Haematol
Autors principals: Siegel, David S., Schiller, Gary J., Song, Kevin W., Agajanian, Richy, Stockerl‐Goldstein, Keith, Kaya, Hakan, Sebag, Michael, Samaras, Christy, Malek, Ehsan, Talamo, Giampaolo, Seet, Christopher S., Mouro, Jorge, Pierceall, William E., Zafar, Faiza, Chung, Weiyuan, Srinivasan, Shankar, Agarwal, Amit, Bahlis, Nizar J.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Haematological Malignancy‐Clinical
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7027539/
https://ncbi.nlm.nih.gov/pubmed/31588567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16213
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars